Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C

• Main Authors: Mehdi ASSMAR (Author), Sara YEGANEH (Author), Fariborz MANSOURGHANAEI (Author), Nour AMIRMOZAFARI (Author)
• Format: Book
• Published: Tehran University of Medical Sciences, 2016-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<p><strong>Background:</strong> This study aimed to determine the role of tumor markers AFP, CA15-3, CA125, CA19-9 and CEA in patients with hepatitis B and C.</p><p><strong>Methods</strong>: This descriptive cross-sectional study was performed from Oct 2012 to Oct 2014. Serum samples of 129 patients with hepatitis B and C referred to Guilan Liver and Digestive Disease Research Center in Rasht, Iran were collected and checked for the existence of the listed tumor markers by ELISA.</p><p><strong>Results:</strong><strong> </strong>No increase in serum levels of tumor marker CA19-9, CEA and CA15-3 were seen in patients with hepatitis (<em>P</em>>0.05). In patients with hepatitis B, increase in CA125 were observed (<em>P</em>=0.03). In hepatitis C patients, there was an increase in AFP levels (<em>P</em>=0.03).</p><p><strong>Conclusion:</strong> The levels of AFP and CA125 markers were high in hepatitis C and hepatitis B, respectively. However, the increased levels were not seen is malignancy. Due to the small sample size, further study is necessary to find the reasons of the increase.</p>

Item Description

2251-6085
2251-6093